Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Common Equity (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Common Equity for 7 consecutive years, with $192.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 56.1% year-over-year to $192.3 million, compared with a TTM value of $192.3 million through Sep 2025, down 56.1%, and an annual FY2024 reading of $388.7 million, up 400.37% over the prior year.
  • Common Equity was $192.3 million for Q3 2025 at Summit Therapeutics, down from $259.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $437.9 million in Q3 2024 and bottomed at $44.2 million in Q1 2024.
  • Average Common Equity over 5 years is $159.9 million, with a median of $119.6 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 66.88% in 2024, then surged 678.85% in 2025.
  • Year by year, Common Equity stood at $83.3 million in 2021, then skyrocketed by 52.07% to $126.7 million in 2022, then plummeted by 38.66% to $77.7 million in 2023, then soared by 400.37% to $388.7 million in 2024, then crashed by 50.54% to $192.3 million in 2025.
  • Business Quant data shows Common Equity for SMMT at $192.3 million in Q3 2025, $259.4 million in Q2 2025, and $344.3 million in Q1 2025.